LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia

Summary

This is a Phase 2, proof of concept, randomized, placebo-controlled, multicenter study to evaluate the ability of LB1148 to attenuate pulmonary dysfunction associated with COVID-19 pneumonia. The primary objective of this study is to determine if enteral administration of LB1148 will effect disease progression in hospitalized patients with moderate to severe COVID-19 via measurement of the proportion of subjects alive and free of respiratory failure at Day 28.

Timeline

Start

2021-10-31

Primary completion

2021-12-31

Completion

2022-03-31

Drugs

Indications